Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era.

Affiliation

Toss A(1), Isca C(2), Venturelli M(2), Nasso C(2), Ficarra G(3), Bellelli V(4), Armocida C(4), Barbieri E(2), Cortesi L(2), Moscetti L(2), Piacentini F(5), Omarini C(2), Andreotti A(6), Gambini A(6), Battista R(7), Dominici M(5), Tazzioli G(8).
Author information:
(1)Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: [Email]
(2)Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
(3)Pathology Unit, University Hospital of Modena, Modena, Italy.
(4)Breast Cancer Screening Service, AUSL Modena, Modena, Italy.
(5)Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
(6)Unit of Breast Surgical Oncology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
(7)Department of Diagnostic Imaging, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
(8)Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; Unit of Breast Surgical Oncology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Abstract

Comment in ESMO Open. 2021 Jun;6(3):100109. ESMO Open. 2021 Jun;6(3):100108.